Sarah Engelbeen, MASc.

Sarah Engelbeen is a PhD student in the DMD Genetic Therapy group since March 2019. Her research focuses on targeting specific pathological pathways with antisense oligonucleotides (AONs) in Duchenne muscular dystrophy and Limb Girdle type 2D and 2F mouse models as a potential therapy for muscular dystrophies.

Click here to see the publication list of Sarah Engelbeen